LP-168

LP-168 · Guangzhou Lupeng Pharmaceutical Company LTD.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for LP-168, covering 2025-08-14 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]